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Gliomas are notoriously aggressive, malignant brain tumors that have variable response
to treatment. These patients often have poor prognosis, informed primarily by histopathol-
ogy. Mathematical neuro-oncology (MNO) is a young and burgeoning field that leverages
mathematical models to predict and quantify response to therapies. These mathematical
models can form the basis of modern “precision medicine” approaches to tailor therapy
in a patient-specific manner. Patient-specific models (PSMs) can be used to overcome
imaging limitations, improve prognostic predictions, stratify patients, and assess treatment
response in silico.The information gleaned from such models can aid in the construction and
efficacy of clinical trials and treatment protocols, accelerating the pace of clinical research
in the war on cancer. This review focuses on the growing translation of PSM to clinical
neuro-oncology. It will also provide a forward-looking view on a new era of patient-specific
MNO.
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THE CLINICAL CHALLENGE OF PATIENT-SPECIFIC
PROGNOSIS AND TREATMENT RESPONSE
Gliomas are heterogeneous primary brain tumors that exhibit
widely varying phenotypes even within the same histological grade
(Louis et al., 2007). These tumors are characterized by proliferating
and invading adjacent normal brain tissue, resulting in a signifi-
cant clinical challenge and generally high morbidity and mortality.
Despite advances in medical imaging technologies, surgery, radia-
tion therapy, and chemotherapies over the last several decades, the
standard of care for newly diagnosed malignant gliomas does not
reflect individual differences (Stupp et al., 2007; Nishikawa, 2010).
Prognosis for glioma patients has hardly changed in over 50 years
of cancer research. The incorporation of patient-specific measures
of prognosis and treatment response allows tailor therapies for
each patient.
INVISIBLE, INHERENT, INVASION
The most significant characteristic of gliomas of all grades is their
diffuse invasion into the normal-appearing brain as seen in gross
pathology and histological specimens. To reduce the morbidity
of extensive biopsies, primary clinical assessment and staging of
Abbreviations: D, net rate of diffusion; FTB, fatal tumor burden; MM, mathematical
modeling; MNO, mathematical neuro-oncology; MRI, magnetic resonance imag-
ing; PSM, patient-specific modeling; ρ, net rate of proliferation; UVC, untreated
virtual control.
gliomas relies on non-invasive radiographic imaging such as mag-
netic resonance imaging (MRI) and computed tomography (CT).
However, neither of these imaging techniques quantifies the full
extent of tumor invasion due to the inherent limits of detection, as
illustrated in Figure 1. Furthermore, post-treatment surveillance
for recurrence and progression is based on these same imaging
technologies (Swanson, 1999; Harpold et al., 2007; Szeto et al.,
2009b; Pallud et al., 2010). The inability to completely quantify
the glioma cell population (invisibility) and diffuse extension into
normal-appearing brain (invasion) along with wide heterogeneity
between and within patients makes a personalized approach to
treatment and measuring response difficult but necessary.
WHY USE MATHEMATICAL MODELING?
Currently, prognosis in glioma patients is based upon retrospec-
tive analyses of groups of patients with similar histopathological
characteristics (Louis et al., 2007). This approach is unsatisfy-
ing because of the heterogeneity of disease phenotypes within
each larger histological category as well as the lack of insight into
treatment modalities that may most benefit an individual patient.
Mathematical models are used to bridge this gap and have been
used to illustrate individual differences in the dynamics of glioma
growth and response to therapy in a research setting, with the
potential for clinical translation on the horizon. To optimize indi-
vidual treatment protocols, physicians and scientists require tools
to evaluate the relative benefit obtained for each patient. The subset
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FIGURE 1 | (A) Concentrations of tumor cells contributing to a gradient of
diffusely invading glioma cells extending well beyond the threshold of
detection. The PI model characterizes the net rates of growth and invasion
of the glioma cells contributing to this overall profile, a sum of individual cell
behaviors. Swanson et al. have demonstrated that D and ρ can be
calculated on a patient-specific basis and can vary widely, even for patients
within the same histological grade (Harpold et al., 2007; Swanson et al.,
2008a; Szeto et al., 2009b; Wang et al., 2009; Rockne et al., 2010). (B) A
simulation of the reaction-diffusion mathematical model on an anatomically
accurate brain phantom (Cocosco et al., 2004) with differential motility in
gray and white matter as proposed by Swanson (1999). The MRI-detectable
edge of the lesion is superimposed as a dark gray contour emphasizing the
extent of invasion well beyond the threshold of detection. From Wang et al.
(2009) with permission from Cancer Research.
of patients with the most aggressive tumors (and inherently worst
prognosis) stand to benefit the most from the shift from one-size-
fits-all treatment to a patient-specific approach, and models allow
for the prospective identification of these patients.
Mathematical models already have a significant impact on clin-
ical practice, as they are widely integrated into medical imaging
technologies (e.g., Carson et al., 1998). Furthermore, mathemati-
cal models are found throughout the biological sciences, with one
of the most common applications being population models for a
single species (e.g., Murray, 2002). Yet it can be quite a leap for
both the basic scientist and clinician to embrace the idea that a
relatively simple mathematical model might shed light on such a
complex disease process as malignant glioma. Some believe that
gliomas are so biologically complex and heterogeneous that no
model could provide insight into the inherent nature of disease.
On the contrary, as clinical oncology strives to provide personal-
ized management of cancer, mathematical models are playing a
pivotal role in providing insight into disease growth, treatment
response, and ultimately building the framework for precision
medicine (Council, 2011).
PATIENT-SPECIFIC MATHEMATICAL NEURO-ONCOLOGY
The term Mathematical Oncology was coined in 2003 to reflect
the burgeoning synergy between mathematical modeling tech-
niques, cancer research, and clinical oncology (Gatenby and Maini,
2003). The term has been subsequently refined to Integrated
Mathematical Oncology to emphasize the feedback that emerges
through the integration of mathematics and oncology (Anderson
and Quaranta, 2008). This review focuses on the patient-specific
applications of Mathematical Neuro-Oncology (MNO) to provide
predictive insight onto glioma prognosis and treatment response
in individual patients. Although the field of neuro-oncology is
broad and encompasses many distinct neoplasms, to date, much
of the literature has been devoted to the presentation of models
and methodologies for estimating glioma growth from medical
imaging and other clinical data.
In this paper, the focus is on models that will truly enable “pre-
cision medicine.” Thus the discussion below will revolve around
only models the authors believe are patient-specific in nature and
have in some way been subjected to validation tests. Specifically
we have reviewed reaction-diffusion models such as those champi-
oned by Swanson, which take a macroscopic perspective of gliomas
as a continuum of tumor cell concentration.
INDIVIDUAL TUMOR GROWTH KINETICS: A PREDICTABLE
PATTERN
Gliomas of all histologic grades exhibit a constant velocity of the
mean tumor radius if left untreated, resulting in predictable pat-
tern of linear radial growth (Swanson and Alvord, 2002; Mandon-
net et al., 2003, 2008; Pallud et al., 2006). Mandonnet et al. (2003)
demonstrated this in 27 untreated low-grade gliomas (LGG) fol-
lowed with serial routine MRI for up to 15 years. Despite the
anatomic heterogeneity in tumor growth, the average radius of
each glioma increased linearly with time, with rates ranging from
1 to 4 mm/year. Furthermore, the velocity of linear radial expan-
sion was shown to predict time to malignant progression (Hlaihel
et al., 2010) and is a significant predictor of survival (Pallud et al.,
2006; Swanson et al., 2008a).
Constant linear radial growth is also seen in a rare example of an
untreated high grade glioma known as glioblastoma multiforme
(GBM). In this case a 75-year-old female presented to the emer-
gency department with a complex partial seizure (CPS), prompt-
ing imaging that revealed a large tumor. She refused medical advice
to undergo a biopsy to establish a diagnosis and subsequent treat-
ment but allowed multiple imaging observations (Swanson and
Alvord, 2002). The patient was found to have a GBM on autopsy,
and the serial imaging revealed a consistent linear radial growth
pattern.
THE PROLIFERATION-INVASION MODEL OF GLIOMA GROWTH
In the early 1990s, the research groups of Murray and Alvord devel-
oped a mathematical model to describe the diffuse infiltration
and proliferation of glioma cells in the complex anatomy of the
human brain (Figure 2). This model can be described in words
as the rate of change of tumor cell density in time is equal to the
net migration of tumor cells plus the net proliferation of tumor
cells. Mathematically, the model is a partial differential equa-
tion with two parameters: net rates of migration (D, mm2/year)
and proliferation (ρ, year−1), both of which can be calculated
on a patient-specific basis using routine clinical imaging prior to
treatment.
rate of change of tumor




net migration of tumor
cells︷ ︸︸ ︷
∇ · (D (x)∇c) +
net proliferation






This “proliferation-invasion” model (PI model) of glioma
growth and infiltration is similar to Fisher’s equation which yields
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FIGURE 2 |Three dimensional simulation of diffuse tumor invasion and
proliferation predicted by the PI model which accounts for differential
motility of tumor cells in gray and white matter. Malignant glioma cells
can migrate up to 100-fold faster in white matter than in gray, characterizing
the extent of invisible subclinical disease.
the same predictable pattern of linear radial growth observed in
low and high grade gliomas (Fisher, 1937). The velocity of growth
predicted by this equation relates the velocity of radial growth to
the square root of the product of net dispersal (D) and prolifera-
tion (ρ) parameters, v = √4Dρ. This relationship combined with
an “invisibility index” (D/ρ) relating rates of invasion and pro-
liferation provides two equations and two unknown parameters,
tuning the PI model to patient-specific growth. The PI model can
further incorporate differential motility of glioma cells through
gray and white matter of the brain, providing predictions of dif-
fuse tumor invasion through the regions of the brain that are
specific to the patient’s tumor (Figure 2). This simple model has
served as a foundation for patient-specific MNO and provided
numerous insights into clinical behaviors such as survival out-
come (Pallud et al., 2006; Swanson et al., 2008b; Wang et al., 2009;
Rockne et al., 2010), hypoxia development (Szeto et al., 2009b),
response to surgical resection (Swanson et al., 2008b), chemo- and
radiation therapies (Rockne et al., 2010), biological aggressiveness
(Szeto et al., 2009a; Ellingson et al., 2010b), and to date is the sin-
gle most applied patient-specific clinical scale model for glioma
growth and response to therapy. Extensions to this model include
consideration of anisotropic growth in white matter tracts (Jbabdi
et al., 2005). Mass effect and mechanical constraints of anatomical
structures such as the skull, have been included to refine spatial
agreement with patient scans (Clatz et al., 2005). Giatili and Sta-
matakos (2012) add adiabatic Neumann boundary conditions to
more realistically model the boundary imposed by the skull. These
efforts show room for further model development, but have yet to
be applied to a patient population as large as that modeled by the
PI model.
Advanced imaging techniques such as diffusion weighted MRI
(DWI), MRI Spectroscopy, and Diffusion Tensor (DT) MRI have
been used to suggest techniques for estimating patient-specific
parameters D and ρ (Ellingson et al., 2010a; Konukoglu et al.,
2010). Based on the assumption that the apparent diffusion coef-
ficient (ADC), which measures magnitude of diffusion of water,
is negatively proportional to tumor cell density, Ellingson et al.
proposes that D and ρ of the PI model, modified such that prolifer-
ation is exponential and not saturated in a saturated environment
can be estimated on a patient-specific basis using three ADC
imaging time points. Ellingson et al. applied this methodology
and found a stratification of D and ρwith histologic grading which
compares well with the previous estimates for high grade gliomas
but differs significantly from the estimates for low-grade prolifer-
ation and invasion kinetics (Harpold et al., 2007). This difference
may be explainable by the fact that the correlations between ADC
and overall tissue cell density utilized by the Ellingson approach
incorporates both normal and malignant cell densities while the PI
model is only tracking the glioma cell density. Further exploiting
opportunities provided by diffusion MRI, Konukoglu et al. (2010)
uses DT-MRI to inform model predictions of separate diffusion
rates in gray and white matter.
“GO OR GROW” HYPOTHESIS
Experimental data suggests that tumor states of proliferative and
invasive capacity are mutually exclusive (Giese et al., 2003). The
“go or grow” hypothesis has influenced mathematical models
analyzing how the rates of switching between proliferative and
migratory phenotypes affect macroscopic tumor growth (Ger-
lee and Nelander, 2012). Hatzikirou et al. (2012) used lattice-gas
cellular automaton models to determine that the rapid recur-
rence of gliomas post-resection cannot be explained by mutation
theory alone, but tumors modeled with “go or grow” behavior
can recapitulate the observed macroscopic growth patterns. Such
models can even suggest treatment strategies, such as tumor oxy-
genation which encourages cells to revert to a proliferative and
less radio- and chemo-resistant state. As Giatili and Stamatakos
(2012) points out, discrete agent and cell based models are bet-
ter suited to answer questions of the biological constitution of
tumors over space and time. Continuum models give better insight
to spatial extent and concentration profile of the population of
tumor cells. Hatzikirou et al. (2012) showed that although the
glioma cell population is heterogeneous and composed of sig-
nificant portions of cells in both proliferative and migratory
states, the microscopic simulation scales up to a reaction-diffusion
model on the macroscopic scale practically identical to the Fisher
equation.
TURNING MATHEMATICAL PREDICTIONS INTO MATHEMATICAL
NEURO-ONCOLOGY
In a review of computational models of brain tumors Juffer et al.
(2008) bemoans a “severe limitation of current models is that they
are in fact not patient-specific at all.”However,mathematical mod-
els come in many forms and with different purposes. Some models
aim to provide qualitative understanding or intuition regarding
the phenomena of interest, while others are intended to provide
predictions for specific scenarios. The effective use of the latter type
of models depends on many factors: defining the quantity of inter-
est, choosing the appropriate model, acquiring data for calibration,
and then successfully subjecting the model to validation tests. By
definition, patient-specific biological models require calibration
for each patient. This inherently leaves room for philosophical
debate regarding sufficient validation tests for patient-specific bio-
logical models, however, a good example for predictions involving
clinical intervention is provided in Figure 3 (Neal and Kerckhoffs,
2010). One should note that this entire type of process would need
to be redone for each possible application of the model.
As might be inferred from Figure 3, the cause of the “limita-
tion” Juffer et al. (2008) raise is due to the difficulty of the entire
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FIGURE 3 | Decision process for patient-specific model validation and translation to clinically applicable analysis. Courtesy: Neal and Kerckhoffs (2010),
by permission of Oxford University Press.
process. The authors are only aware of work based on such an
outline in the context of gliomas by the Swanson group (Swanson
et al., 2002a, 2008b; Szeto et al., 2009b; Wang et al., 2009; Neal
and Kerckhoffs, 2010; Rockne et al., 2010; Baldock et al., 2012a,b;
Gu et al., 2012; Neal et al., 2012, 2013). But that is not to say that
other efforts are not informative or useful. Indeed, many papers
have been published (e.g., Zacharaki et al., 2009; Konukoglu et al.,
2010), considering the formidable technical details involved in
development and validation of a mathematical model that can be
used to inform clinical decision making.
Additionally, models may be used for qualitative understanding
of events. An example of such work is that by Bohman et al. (2010)
where they investigated ontogeny and spatio-temporal evolution
of gliomas. By looking at a set of 63 patient tumors, they deter-
mined that tumors abutting the ventricle in the sub ventricular
zone (SVZ) are larger than those that do not (Figure 4). The sim-
ulation results then pointed to an explanation in that two tumors
with identical growth rates, as defined by the continuum mathe-
matical model, could display markedly different growth patterns
due to the anatomy of the brain and ontogeny of the tumor. Thus,
it is not necessary for a mathematical model to be patient-specific
to produce clinically significant results.
PROGNOSIS OF INDIVIDUAL PATIENTS USING PRE-TREATMENT
TUMOR GROWTH KINETICS
In a study of 32 newly diagnosed glioblastoma patients, Wang
et al. (2009) used the PI model to find relationships between
the Patient-specific model (PSM) parameters for glioma cell net
dispersal (D), proliferation (ρ), and prognosis. As illustrated in
Figure 1, patient-specific estimates D and ρ combine with the
patient’s MRI to yield a map of the diffuse gradient of glioma
cells that is expected to lie beyond thresholds visible to imaging
(Figure 1). Wang et al. analyzed patient-specific tumor growth
kinetics relative to the patients’ actual survival and found that
the model parameters (specifically, ρ and ρ/D) were signifi-
cant predictors of prognosis in both univariate and multivariate
analyses even when controlling for standard clinical prognostic
parameters such as RTOG recursive partitioning analysis (RPA)
classification.
Velocity of radial expansion on MRI and net proliferation rates
were compared to RPA classification and it was found that patients
with low velocity and proliferation lived longer than the median
prognosis associated with each RPA class, and patients with high
velocity and proliferation had shorter survival. A therapeutic
response index (TRI) was also calculated for each patient. This
is defined as the ratio between the patient’s actual survival, and
the time it takes for their untreated virtual control (UVC) tumor
to reach fatal tumor burden (FTB) (Swanson, 2008; Wang et al.,
2009). Patients with high rates of proliferation and velocity were
found to have higher TRIs (Wang et al., 2009). This paper was per-
haps the first in the literature for which a patient calibrated mathe-
matical model for glioma growth generated prognostic parameters
in a patient cohort.
QUANTIFYING TUMOR AGGRESSIVENESS IN INDIVIDUAL PATIENTS
Despite the predictable pattern of linear radial growth in gliomas,
within histologic grade there may be great variability in response
to treatment and overall prognosis (Bonavia et al., 2011). The
hypothesis that more aggressive tumors are more hypoxic was
tested using PI model metrics of biological aggressiveness. Szeto
et al. (2009b) found there was a strong relationship between
hypoxia and the ratio of PI model parameters for proliferation and
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FIGURE 4 | “Example screenshots from glioma growth model
simulations with varied points of origin. Images at four time points each
for three simulated lesions provided in the sagittal, coronal, and axial planes
for lesion start points at the anterior dorsolateral subventricular zone, anterior
deep white matter, and anterior superficial white matter. Green area reflects
estimated T2-weighted image abnormality on magnetic resonance; red area
reflects estimated T1-weighted image post-gadolinium abnormality.”
Courtesy: Bohman et al. (2010).
FIGURE 5 | Scatter plot of relative hypoxia (RH, the ratio of hypoxic
volume toT2-weighted MRI volume) versus ρ/D for n=11
glioblastoma patients. RH was determined over a variety of tissue to
blood (T/B) tracer levels, ranging from 1.1 to 1.6 in increments of 0.1. A
strong linear relationship between the variables is shown for all thresholds;
correlations were statistically significant for all T/B levels considered. From
Szeto et al. (2009b), with permission from Nature Publishing Group, Cancer
Research.
diffusion on 11 glioblastoma patients (Figure 5). Relative hypoxia
(RH) was computed as the ratio of hypoxic volume obtained from
pre-treatment 18F-Fluoromisonidazole (FMISO) PET images to
the region of hyper intensity on T2-weighted MRI. They found
that a tumor with high proliferation relative to diffusion would be
a relatively well demarcated lesion, while a low ratio would indi-
cate a very diffuse tumor with more migratory capacity compared
to the proliferation rate. A metric of tumor shape irregularity was
also calculated and found to be negatively correlated with ρ/D.
This suggests that more irregularly shaped tumors are formed
by cells with relatively high proliferation rates in highly hypoxic
environments. These metrics yield patient-specific understand-
ing and quantification of disease burden and relative biological
aggressiveness and a tool in the MNO toolbox.
GOING BEYOND THE ROUTINE: ADVANCED IMAGING IN
MATHEMATICAL MODELING
Extending the PI spatio-temporal model of glioma prolifer-
ation and invasion, Swanson’s group (Swanson et al., 2011;
Gu et al., 2012) incorporated neoangiogenesis-a defining hall-
mark of high grade glioma into the PI model. Briefly, this
Proliferation-Invasion-Hypoxia-Necrosis-Angiogenesis (PIHNA)
model includes invading normoxic glioma cells which become
hypoxic when local resources are exhausted. This results in the
local production of significant amounts of angiogenic factors
that, in turn, stimulate an angiogenic response. If the angio-
genic response is sufficiently robust, these hypoxic cells may revert
to normoxia; however, if the angiogenic response is insufficient
then necrosis may result. Patient-specific simulations of this type
allow for the generation of spatio-temporal maps of normoxic
cells, hypoxic cells, necrotic tissue, vascular volume fraction, and
angiogenic factors.
The PIHNA model predicts a patient-specific spatial map of
hypoxia, which can be compared with PET imaging with the
hypoxia tracer 18F-FMISO (Gu et al., 2012). Since there is sig-
nificant image noise introduced from PET image acquisition and
reconstruction, a combination of a pharmacokinetic model for
the FMISO tracer kinetics and an image reconstruction algorithm
for PET were applied to the patient-specific simulated hypoxic cell
distribution to generate a patient-specific in silico PET image with
striking similarity to the patient’s actual image (Figure 6).
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FIGURE 6 | Simulated FMISO-PET and actual FMISO-PET.
Hypoxia is predicted by the PIHNA model and an imaging
reconstruction algorithm produces the simulated FMISO-PET. Pixel
intensity distribution is not statistically different between the two
images, providing model-based predictions of tumor hypoxia
which is otherwise obscured by PET image acquisition and
reconstruction. Courtesy: Gu et al. (2012), by permission of Oxford
University Press.
THE UNTREATED VIRTUAL CONTROL
To date, the most effective demonstration of the clinical utility of
mathematical modeling has been in the context of UVC (Figure 7)
(Swanson, 2008; Wang et al., 2009). The concept of an UVC is
that a model that accurately describes the inherent, untreated dis-
ease behavior as a baseline for future comparisons for a specific
patient. Deviations from the predicted “control” behavior can be
assessed and used as a metric of response to therapy. Because
gliomas have a simple, predictable pattern of untreated growth,
the UVC approach is particularly simple to apply in this case.
TREATMENT RESPONSE AND OPTIMIZATION
Few treatment options exist for newly diagnosed glioma beyond
surgery and chemoradiation following the landmark study which
established standard of care for the disease (Stupp et al., 2007).
Novel therapies are often reserved for the recurrent setting and
have shown little benefit in prolonging survival. Due to the relative
rarity of the disease, powering clinical studies can be challenging.
Mathematical models quantifying response, sensitivity, and rela-
tive benefit of treatment (UVC) provide a novel and alternative
means of stratifying patients for clinical studies.
DAYS GAINED SCORE AS A TREATMENT RESPONSE METRIC
The Days Gained score provides a measure of patient-specific
treatment derived benefit in terms of treatment induced deflec-
tion in tumor growth from the UVC (Neal et al., 2013). This
novel quantification stands in stark contrast to current metrics of
response (e.g., Macdonald criteria, RANO, and RECIST) that do
not account for the relative growth kinetics of individual tumors.
One clear difference is that static imaging-based metrics allow a
poor response for a slow growing tumor to be equated with a
significant response from a fast growing tumor. Neal has shown
that the Days Gained metric indeed performs better than these
existing metrics in determining patients that will have a survival
benefit from treatment. While these classic response criteria are
actively being reconsidered in the context of gliomas (Wen et al.,
2010), the UVC PSM represents an opportunity to incorporate the
implicit heterogeneity of glioma growth kinetics across patients
into measures of treatment response.
SURGICAL RESECTION
Surgical resection is the first line response to clinical presen-
tation and radiographic diagnosis of a malignant brain tumor.
Although the survival benefit of subtotal (STR) versus gross total
(GTR) removal of imageable tumor remains controversial, Swan-
son et al. (2008b) used mathematical modeling to simulate surgical
resection using the PI model for 70 glioblastoma patients using
contrast-enhanced T1-weighted MRI volume and radial veloc-
ity of tumor growth. The model was able to predict the survival
curve for biopsy and subtotal resection groups (Figure 8A). Sim-
ulations were performed to represent 100 and 125% resections,
the observed gross total resection survival curve was found to lie
between these two virtual curves (Figure 8B). These results sug-
gest that although GTR provides a survival benefit over patients
receiving biopsies or subtotal resections, this is partially due to
the preferential selection of patients with smaller tumors for gross
total resection. This analysis, made possible with mathematical
modeling, provides valuable insight into a controversial clinical
debate.
QUANTIFYING AND PREDICTING RESPONSE TO RADIATION THERAPY
Beyond RECIST and Macdonald response criteria (Padhani and
Ollivier, 2001; Galanis et al., 2006; Therasse et al., 2006), quantify-
ing the in vivo biological effectiveness of radiotherapy in individual
patients has remained elusive (Enderling et al., 2010). Rockne et al.
(2009, 2010) incorporated the classic linear-quadratic model for
radiation effectiveness (Bauman et al., 1999; Sachs et al., 2001)
into the PI model to quantify the effectiveness of radiotherapy
in individual glioma patients. The extended model (PIRT) uses
radiation dose plans from the clinical treatment system and frac-
tionation – e.g., 1.8 Gy fractions delivered to the T2 abnormality
with a 2.5-cm margin. Nine glioblastoma patients with two MRIs
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FIGURE 7 | Comparisons between untreated virtual controls and
post-treatment MRI scans. First row: post-treatment MRI. Second row:
contours showing measured tumor on T1-Gd-enhanced scan (red) and UVC
prediction of T1-Gd area (aqua). Third row: UVC tumor cell densities overlaid
(white, high cell density; red, low cell density) on scan with T1-Gd measured
tumor outline (black).
before the initiation of radiotherapy and at least one MR after
the completion of radiation therapy were included in the study.
The authors found a strong correlation between the net prolifera-
tion rate (ρ) of the glioma cells before the initiation of treatment
and the radiation effectiveness (Figure 9). The predictive preci-
sion of this relationship was tested with a leave one out cross
validation (LOOCV) analysis which revealed an average 2.4 mm
difference between simulated and actual tumor volume post RT
which given an average GBM radius of 2 cm represents a relative
error of at most 15%. The error is substantially more resolved than
the 25% categories presented in RECIST or Macdonald criteria
(Padhani and Ollivier, 2001; Therasse et al., 2006). This approach
has provided the first in vivo quantification of radiosensitivity
in individual glioma patients as well as a predictive relationship
between pre-treatment growth kinetics and response to therapy.
In silico models of tumor growth and response to radiother-
apy allow for the investigation of factors affecting radiosensitivity
and alternative treatment strategies that may be impractical in
the clinic. Stamatakos et al. (2006) model studies the interde-
pendent effects of oxygenation on radiosensitivity, angiogene-
sis, and clonogenic cell density on tumor growth. Lower oxy-
gen enhancement ratio and lower clonogenic cell density were
among the factors found to increase radiosensitivity, agreeing with
clinical experience, although not directly compared with clini-
cal data. Both Powathil et al. (2007) and Rockne et al. (2009)
used a continuum reaction-diffusion model along with the clas-
sic linear-quadratic model for radiotherapy effect to investigate
alternative fractionation strategies on a virtual tumor with fixed
tumor growth kinetics and radio sensitivity. To date, neither model
has incorporated the toxic effects of radiation on normal tissue.
Holdsworth et al. (2012) builds upon these foundations by refining
intensity-modulated radiation therapy (IMRT) plans based on
the criteria of maximizing cytotoxicity while minimizing normal
tissue dose.
Swanson et al. (2008a) used the concept of a UVC to under-
stand relative treatment response effects on individual survival
time assuming a FTB (Concannon et al., 1960). Results of this
investigation demonstrate that patient-specific rates of invasion
and proliferation as estimated by a reaction-diffusion model can
be calculated for individual patients and related to radio-resistance
or radiosensitivity in individual patients and that the mathematical
model can be used to determine radio efficacy by relating survival
times predicted by the UVC to that observed in the patients, assum-
ing a FTB. In this population, Swanson et al. were able to identify
those patients that benefited significantly from radiotherapy by
comparing model-predicted untreated survival time with actual
(treated) survival time.
OPTIMIZING RADIATION THERAPY
In silico models of tumor growth and response to radiotherapy
allow for the investigation of alternative treatment strategies that
may be impractical in the clinic. Holdsworth et al. (2012) leveraged
the patient-specific description of tumor growth and response
in the PIRT model (Rockne et al., 2010) to generate biologically
guided treatment plans. Using an adaptive, multiobjective evo-
lutionary algorithm (MOEA), IMRT plans were optimized with
respect to a variety of clinical objectives including maximizing
normal tissue sparing and minimizing the tumor burden at vari-
ous time points. By using the PIRT model-predicted tumor burden
12 weeks post-irradiation as an optimization objective for each
week of simulated treatment, the MOEA computed radiotherapy
plans that improved treatment gain by an average of 122.5 days
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FIGURE 8 | “(A) Survival curves for actual glioblastoma patients (asterisks)
and virtual patients (squares) subjected to biopsy or subtotal resection
(BX/STR, N =38). Inset shows a close-up of the survival curves near the
median survival times of 32.4 and 36.5 weeks. (B) Survival curves on a
longer time scale following gross total resection (GTR, N = 32) in actual
patients (asterisks) defined by the absence of residual tumor on
post-operative enhanced CT. The virtual patients (matched to actual
pre-operative T1-Gd volume and D/ρ ratio derived from the T1-Gd and T2
volumes) were subjected to no resection (BX/STR, squares), to resection of
100% of the T1-Gd volumes or radii, rT1 (circles), and to resection of 125%
of the T1-Gd volumes or radii, 1.25 rT1 (diamonds). Inset shows a close-up
of the survival curves near the median survival times of 44.9, 55, 62, and
66.9 weeks.” Reprinted from Swanson et al. (2008b) with permission from
Nature Publishing Group, British Journal of Cancer.
and reduced equivalent uniform dose (EUD) to normal tissue an
average of 15.5 Gy for two example patients (Holdsworth et al.,
2012).
PREDICTING PSEUDOPROGRESSION
Pseudoprogression is a puzzling clinical phenomenon defined
by increased contrast enhancement on MRI within 100 days of
radiation therapy that spontaneously improves with no subse-
quent change in treatment (Brandsma et al., 2008). It has been
estimated that 20–47% of tumors exhibiting increased contrast
enhancement on MRI within 12 weeks following chemoradio-
therapy are not indicative of true progressive disease, but are a
result of pseudoprogression (Brandsma et al., 2008; Clarke and
Chang, 2009). This poses a significant clinical challenge as the
FIGURE 9 | (A) “Response to therapy is conventionally assessed by
determining changes in gross tumor volume (GTV) on MRI prior to and after
the administration of therapy. Post-contrast T1-weighted MRI images are
shown for two glioblastoma patients that would typically be separated into
generic groups: responder and stable disease. The radiation response
parameter α gives an additional quantification of radiation response for each
patient.” (B) “Relationship between radiation response and tumor
proliferation rate parameters α (Gy−1) and ρ (1/year), respectively, with α
calculated relative to changes in T2 GTV post therapy r = 0.89, ρ0.05,
N =9. Error bars on ρ are calculated by propagation of error in
pre-treatment GTV as assessed by inter-observer variability of ±1 mm in
equivalent spherical radius. Error bars in α are computed by taking the
maximum and minimum values of α in a leave one out cross validation
(LOOCV) technique.” Courtesy: Rockne et al. (2010), with permission from
IOP Publishing Ltd.
current standard of care for recurrent glioma disease calls for
immediate changes to chemotherapeutic regimens upon clinical
assessment of tumor progression as indicated by increased con-
trast enhancement on MRI. In addition, recurrent glioma disease
is often treated with a second surgical resection of the T1-weighted
gadolinium enhanced region (Stupp et al., 2010). Although there
is currently no understanding of the underlying biological mech-
anisms to understand and predict which patients will exhibit
pseudoprogression, the Days Gained metric has been shown to dis-
criminate pseudoprogression from true progression in individual
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patients (Neal et al., 2013). Patients with pseudoprogression were
found to have significantly higher Days Gained scores, connecting
model-based metrics of response to clinical outcomes in individual
patients.
SUMMARY
Gliomas present a unique clinical challenge. In addition to intra-
and inter-tumoral heterogeneity, these lesions are defined by
their diffuse invasion of otherwise normal-appearing brain tis-
sue peripheral to the imageable abnormality. This diffuse growth
limits the clinical utility of neuroimaging in interpreting treatment
response. Current metrics of therapeutic response rely on observ-
able changes to clinical imaging (Wen et al., 2010), ignoring the
underlying growth dynamics of the tumor. Further, the current
standard of care leaves few treatment options and may over-treat
patients with slow growing tumors. Patient-specific mathematical
modeling provides a novel means of developing UVCs for each
patient’s tumor and provides predictive insight into prognosis,
treatment response, and optimal treatment design.
The future of patient-specific modeling and application
depends on asking questions that mathematical models can realis-
tically answer with data that can be obtained from patients either
non-invasively or infrequently. PSM must be validated and incor-
porated into clinical trials to become broadly and directly applic-
able to patient care. Advantages of a patient-specific modeling
approach include:
◦ Identification of individualized tumor proliferation and inva-
sion rates or other kinetic information about an individual
patient’s tumor (Swanson et al., 2002b; Mandonnet et al., 2003;
Pallud et al., 2006; Harpold et al., 2007; Swanson, 2008; Szeto
et al., 2009a,b; Wang et al., 2009; Boone et al., 2010; Rockne
et al., 2010; Gu et al., 2012)
◦ Development of methods for quantifying and predicting
response to therapy – alone and also with respect to UVCs pro-
vided by model predictions (Swanson et al., 2008a; Wang et al.,
2009; Rockne et al., 2010)
◦ More informed treatment planning and response assessment
tools that compare each patient’s tumor growth against its own
virtual control (Swanson et al., 2002a, 2008a,b; Harpold et al.,
2007; Szeto et al., 2009b; Wang et al., 2009; Rockne et al., 2010;
Gu et al., 2012)
These advantages directly address a number of key unmet chal-
lenges in clinical neuro-oncology. In the coming years we antic-
ipate a continued expansion of peer-reviewed journals dedicated
to mathematical oncology, coordinated with increased funding for
research in the area. Recently, Cancer Research has added a spe-
cial section devoted exclusively to mathematical oncology, and the
NIH has initiated special funding programs targeted at mathemat-
ical models through the Integrative Cancer Biology Program and
Physical Sciences Oncology Center, among others. By producing
individualized virtual tumors that predict disease progression in
the absence of treatment, patient-specific modeling can contribute
to the ongoing dialog regarding the design of appropriate response
criteria (Wen et al., 2010), provide a means to perform virtual clin-
ical trials to assess the likely benefit of novel neurotherapeutics,
and move neuro-oncology toward individualized treatment plans
optimized for maximum benefit.
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